Peptonic Medical (PMED) Q4 2025 earnings summary

Executive summary

• Significant restructuring led to a streamlined business focused on core intimate health products, with discontinued unprofitable subsidiaries and products.

• Strategic focus shifted to proprietary product portfolio and international expansion, especially through new distribution agreements.

• Cost reductions and organizational changes resulted in improved operational efficiency and profitability.

Financial highlights

• Q4 2025 sales of goods: 3,539 KSEK, down 20% year-over-year; full-year sales: 14,788 KSEK, down from 26,891 KSEK.

• Q4 gross profit: 2,165 KSEK (gross margin 61% vs. 58% prior year); full-year gross profit: 9,953 KSEK (margin 67% vs. 56%).

• Q4 operating result: 998 KSEK (vs. -26,749 KSEK prior year); full-year operating result: -19,449 KSEK (vs. -58,648 KSEK).

• Q4 EPS: 0.0000001 SEK (vs. -0.005 SEK); full-year EPS: -0.000003 SEK (vs. -0.0170 SEK).

• Cash at year-end: 195 KSEK (vs. 3,740 KSEK prior year); equity: 38,245 KSEK (soliditet 58%).

Outlook and guidance

• Focus on international growth, especially in the US, Canada, Mexico, and the UK via new distribution agreements.

• Continued product development and portfolio expansion to drive future revenue streams.

• Ongoing recruitment for a permanent CEO and further strategic refinement.